Literature DB >> 19960278

Gastrointestinal stromal tumors (GIST): a prospective evaluation of risk factors and prognostic scores.

Juan Manuel Sanchez Hidalgo1, Sebastian Rufian Peña, Ruben Ciria Bru, Alvaro Naranjo Torres, Cristobal Muñoz Casares, Juan Ruiz Rabelo, Javier Briceño Delgado.   

Abstract

INTRODUCTION: Many risk scores for malignancy in gastrointestinal stromal tumors (GISTs) are based on the combination of size, mitotic index, and location in order to predict recurrence, appearance of metastases, or survival.
DESIGN: This is a prospective analysis of prognosis factors (size, mitotic index, Ki-67, and others) and malignancy risk scores (Fletcher's, modified NIH, Miettinen, NCCN, and A or B Goh's scores). This is a study of the sensitivity and specificity of the different malignancy risk scores in the prognosis of recurrence and survival.
MATERIALS AND METHODS: We operated on 52 patients from 1 January 2002 to 10 January 2008. Mean follow-up was 35 months. We used SPSS 13.0 for Windows for the statistical analysis. The differences between frequencies and means were calculated using the chi-square test, Student's t test, and analysis of variance. Kaplan-Meier and the Cox multiple regression methods were used to calculate overall and disease-free survival. Sensitivity and specificity were depicted graphically as receiver operating characteristic (ROC) curves.
RESULTS: Thirteen patients suffered recurrences (27.7%). Eleven died from disease-related causes. Two-year and 5-year actuarial survival was 80% and 76%, respectively, and the mean survival was 60 months (CI 95% 51.9-69.5). Two-year and 5-year actuarial disease-free survival was 76% and 72% respectively, and the mean disease-free survival was 52 months (CI 95% 43.5-61.1). The score proposed by Fletcher has the greatest sensitivity and specificity in our series to predict overall survival (AUROC = 0.761; SE 0.084, p = 0.009; CI 95% 0.597-0.926) and recurrence (AUROC RECURRENCE = 0.693; SE 0.087, p = 0.042; CI 95% 0.523-0.864) compared with other scores.

Entities:  

Mesh:

Year:  2010        PMID: 19960278     DOI: 10.1007/s12029-009-9102-y

Source DB:  PubMed          Journal:  J Gastrointest Cancer


  20 in total

1.  Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival.

Authors:  R P DeMatteo; J J Lewis; D Leung; S S Mudan; J M Woodruff; M F Brennan
Journal:  Ann Surg       Date:  2000-01       Impact factor: 12.969

2.  Gastrointestinal stromal tumors: analysis of clinical and pathologic factors.

Authors:  C J Kim; S Day; K A Yeh
Journal:  Am Surg       Date:  2001-02       Impact factor: 0.688

3.  Prognostic factors after surgery of primary resectable gastrointestinal stromal tumours.

Authors:  T Aparicio; V Boige; J-C Sabourin; P Crenn; M Ducreux; A Le Cesne; S Bonvalot
Journal:  Eur J Surg Oncol       Date:  2004-12       Impact factor: 4.424

4.  [Gastrointestinal stromal tumors (GIST): factors predictive of survival after R0-cytoreduction].

Authors:  J M Sánchez Hidalgo; F C Muñoz Casares; S Rufian Peña; A Naranjo Torres; R Ciria Bru; J Briceño Delgado; P López Cillero
Journal:  Rev Esp Enferm Dig       Date:  2007-12       Impact factor: 2.086

5.  Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST).

Authors:  Ronald P Dematteo; Jason S Gold; Lisa Saran; Mithat Gönen; Kui Hin Liau; Robert G Maki; Samuel Singer; Peter Besmer; Murray F Brennan; Cristina R Antonescu
Journal:  Cancer       Date:  2008-02-01       Impact factor: 6.860

Review 6.  Diagnosis of gastrointestinal stromal tumors: A consensus approach.

Authors:  Christopher D M Fletcher; Jules J Berman; Christopher Corless; Fred Gorstein; Jerzy Lasota; B Jack Longley; Markku Miettinen; Timothy J O'Leary; Helen Remotti; Brian P Rubin; Barry Shmookler; Leslie H Sobin; Sharon W Weiss
Journal:  Hum Pathol       Date:  2002-05       Impact factor: 3.466

7.  Which is the optimal risk stratification system for surgically treated localized primary GIST? Comparison of three contemporary prognostic criteria in 171 tumors and a proposal for a modified Armed Forces Institute of Pathology risk criteria.

Authors:  Brian K P Goh; Pierce K H Chow; Wai-Ming Yap; Sittampalam M Kesavan; In-Chin Song; Pradeep G Paul; Boon-Swee Ooi; Yaw-Fui A Chung; Wai-Keong Wong
Journal:  Ann Surg Oncol       Date:  2008-06-11       Impact factor: 5.344

Review 8.  NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines.

Authors:  George D Demetri; Robert S Benjamin; Charles D Blanke; Jean-Yves Blay; Paolo Casali; Haesun Choi; Christopher L Corless; Maria Debiec-Rychter; Ronald P DeMatteo; David S Ettinger; George A Fisher; Christopher D M Fletcher; Alessandro Gronchi; Peter Hohenberger; Miranda Hughes; Heikki Joensuu; Ian Judson; Axel Le Cesne; Robert G Maki; Michael Morse; Alberto S Pappo; Peter W T Pisters; Chandrajit P Raut; Peter Reichardt; Douglas S Tyler; Annick D Van den Abbeele; Margaret von Mehren; Jeffrey D Wayne; John Zalcberg
Journal:  J Natl Compr Canc Netw       Date:  2007-07       Impact factor: 11.908

9.  Results of aggressive treatment of gastric sarcoma.

Authors:  W Carson; C Karakousis; H Douglass; U Rao; M L Palmer
Journal:  Ann Surg Oncol       Date:  1994-05       Impact factor: 5.344

Review 10.  Clinical presentation of gastrointestinal stromal tumors and treatment of operable disease.

Authors:  Peter J Roberts; Burton Eisenberg
Journal:  Eur J Cancer       Date:  2002-09       Impact factor: 9.162

View more
  6 in total

1.  Impact of serosal involvement/extramural growth on the risk of synchronous and metachronous peritoneal spread in gastrointestinal stromal tumors: proposal for a macroscopic classification of GIST.

Authors:  Abbas Agaimy; Nikolaos Vassos; Peter H Wunsch; Werner Hohenberger; Arndt Hartmann; Roland S Croner
Journal:  Int J Clin Exp Pathol       Date:  2012-01-01

Review 2.  Gastrointestinal stromal tumors (GIST) from risk stratification systems to the new TNM proposal: more questions than answers? A review emphasizing the need for a standardized GIST reporting.

Authors:  Abbas Agaimy
Journal:  Int J Clin Exp Pathol       Date:  2010-05-05

3.  Potential indicators predict progress after surgical resection of gastrointestinal stromal tumors.

Authors:  Qinggang Hu; Shanglong Liu; Jianwei Jiang; Chen Zhang; Xiaowei Liu; Qichang Zheng
Journal:  Front Med       Date:  2012-07-14       Impact factor: 4.592

Review 4.  Gastrointestinal stromal tumors: A multidisciplinary challenge.

Authors:  Juan Manuel Sanchez-Hidalgo; Manuel Duran-Martinez; Rafael Molero-Payan; Sebastian Rufian-Peña; Alvaro Arjona-Sanchez; Angela Casado-Adam; Antonio Cosano-Alvarez; Javier Briceño-Delgado
Journal:  World J Gastroenterol       Date:  2018-05-14       Impact factor: 5.742

5.  Prolonged Therapy with Imatinib Mesylate before Surgery for Advanced Gastrointestinal Stromal Tumor Results of a Phase II Trial.

Authors:  C Doyon; L Sidéris; G Leblanc; Y E Leclerc; D Boudreau; P Dubé
Journal:  Int J Surg Oncol       Date:  2012-12-17

6.  Increased ski expression levels are associated with a higher risk and poor prognosis in patients with gastrointestinal stromal tumors.

Authors:  Qiu-Shi Wang; Yu Zhai; Ping Li; Hua-Liang Xiao; Yuan-Guo Zhou
Journal:  Oncol Lett       Date:  2020-01-09       Impact factor: 2.967

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.